Memory
C, limited. No effect foundEvidence maturity: Established
Why C, and history for Memory
Every controlled human memory trial found tested Souvenaid (Fortasyn Connect), a drink combining UMP with omega-3 fats, choline, B vitamins and other nutrients, in people with Alzheimer's disease, so no effect can be attributed to uridine and results may not apply to healthy adults. Two manufacturer-funded trials in mild disease reported memory gains, but a Cochrane review of three low-risk-of-bias trials judged that it probably makes little or no difference to cognitive function. A small pilot RCT in children using a DHA, vitamin D3 and uridine supplement could not show a cognitive effect; 14 of 16 children completed and its own power calculation called for 26. Animal work in gerbils supports the mechanism only. The best synthesis, a Cochrane review, found probably little or no difference in global or specific cognitive functions, so the direction is none (limited, mixed) rather than benefit.
Rubric condition met: C: results only in clinical populations being extrapolated to healthy adults; every memory RCT found used a multinutrient drink (UMP with omega-3s, choline, B vitamins and more) in people with Alzheimer's disease; no RCT of uridine alone in healthy adults
Grade history
- : Graded C (awaiting approval)
- : C to C (awaiting approval). The combination rule puts the multinutrient-drink context on the grade; direction changed from benefit to none because the Cochrane review of three low-risk-of-bias trials found probably little or no difference and the only healthy-population trial (children) could not show an effect but was underpowered by its own calculation (14 of 16 completed, 26 needed), so it adds little either way, while the positive memory results come from manufacturer-funded trials.
- : C to C (awaiting approval). Maturity, bias summary and re-check date added
- : C to C (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page
How sure are we? Memory
Evidence maturity: Established Established for the Souvenaid multinutrient drink in Alzheimer's disease (Cochrane review of 3 low-risk trials); for uridine itself, Mechanistic only.
Tested as: Uridine monophosphate inside the Souvenaid multinutrient drink
- Who paid for the studies
- All industry-funded
- Risk of bias
- Low. Every Souvenaid trial is manufacturer-linked (Nutricia).
- Trial registry check
- Not checked yet
- Outcome measured
- A test score, rating scale or performance measure
- Who was studied
- Clinical populations only
- Material tested
- Within a multinutrient drink (Souvenaid)
- Rules applied
- Population cap (logged, no further change): Alzheimer's disease; Combination only (logged, no further change): Multinutrient drink only; B2: one funder or group (logged, no further change): One manufacturer behind every trial
- Could rise: Would move to C benefit for uridine alone with a preregistered RCT of uridine or UMP alone, of adequate size, positive on a memory primary outcome.
- Could fall: Would move to N for the drink if a second Cochrane-quality synthesis restricted to low-risk trials were null.
Science is provisional. This grade reflects the evidence we found as of . Next review: .